| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8877938 | NOVARTIS PHARMS CORP | Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations |
May, 2027
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8404744 | NOVARTIS PHARMS CORP | Methods of treatment and pharmaceutical composition |
Jan, 2023
(1 year, 3 months ago) | |
| US8796331 | NOVARTIS PHARMS CORP | Methods of treatment and pharmaceutical composition |
Jan, 2023
(1 year, 3 months ago) | |
|
US8404744 (Pediatric) | NOVARTIS PHARMS CORP | Methods of treatment and pharmaceutical composition |
Jul, 2023
(9 months ago) | |
|
US8796331 (Pediatric) | NOVARTIS PHARMS CORP | Methods of treatment and pharmaceutical composition |
Jul, 2023
(9 months ago) | |
| US7468390 | NOVARTIS PHARMS CORP | Methods of treatment and pharmaceutical composition |
Nov, 2023
(4 months ago) | |
|
US7468390 (Pediatric) | NOVARTIS PHARMS CORP | Methods of treatment and pharmaceutical composition |
May, 2024
(a month from now) | |
| US8101659 | NOVARTIS PHARMS CORP | Methods of treatment and pharmaceutical composition |
Jan, 2025
(8 months from now) | |
|
US8101659 (Pediatric) | NOVARTIS PHARMS CORP | Methods of treatment and pharmaceutical composition |
Jul, 2025
(1 year, 2 months from now) | |
| US9388134 | NOVARTIS PHARMS CORP | Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations |
Nov, 2026
(2 years from now) | |
|
US9388134 (Pediatric) | NOVARTIS PHARMS CORP | Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations |
May, 2027
(3 years from now) | |
|
US8877938 (Pediatric) | NOVARTIS PHARMS CORP | Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations |
Nov, 2027
(3 years from now) | |
| US11135192 | NOVARTIS PHARMS CORP | Inhibitors for treating diseases characterized by atrial enlargement or remodeling |
Aug, 2033
(9 years from now) | |
| US9517226 | NOVARTIS PHARMS CORP | Inhibitors for treating diseases characterized by atrial enlargement or remodeling |
Aug, 2033
(9 years from now) | |
| US9937143 | NOVARTIS PHARMS CORP | Inhibitors for treating diseases characterized by atrial enlargement or remodeling |
Aug, 2033
(9 years from now) | |
| US11058667 | NOVARTIS PHARMS CORP | Sacubitril-valsartan dosage regimen for treating heart failure |
May, 2036
(12 years from now) | |
Entresto is owned by Novartis Pharms Corp.
Entresto contains Sacubitril; Valsartan.
Entresto has a total of 16 drug patents out of which 5 drug patents have expired.
Expired drug patents of Entresto are:
- US8404744
- US8796331
- US8404744*PED
- US8796331*PED
- US7468390
Entresto was authorised for market use on 07 July, 2015.
Entresto is available in tablet;oral dosage forms.
Entresto can be used as treatment of heart failure, treatment of heart failure with preserved ejection fraction, treating chronic heart failure with reduced ejection fraction in patients not taking an ace inhibitor or an arb or previously taking low doses of these agents, by titrating up from half the usually recommended starting dose.
Drug patent challenges can be filed against Entresto from 01 April, 2022.
The generics of Entresto are possible to be released after 09 May, 2036.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-82) | Feb 16, 2024 |
| Pediatric Exclusivity(PED) | Apr 01, 2023 |
| New Chemical Entity Exclusivity(NCE) | Jul 07, 2020 |
| New Patient Population(NPP) | Oct 01, 2022 |
Drugs and Companies using SACUBITRIL; VALSARTAN ingredient
NCE-1 date: 01 April, 2022
Market Authorisation Date: 07 July, 2015
Treatment: Treatment of heart failure; Treatment of heart failure with preserved ejection fraction; Treating chronic heart failure with reduced ejection fraction in patients not taking an ace inhibitor or an arb...
Dosage: TABLET;ORAL
ENTRESTO family patents
